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Abstract
Background: The development of resistance to hormone therapy in both breast and prostate
cancers is attributed to tens of thousands of patient deaths every year.
Results: From analyses of global gene expression profile data, a nonrandom amount of overlap was
observed between the set of genes associated with estrogen receptor negative (ER-), hormone
independent breast cancer and the set of genes associated with androgen independent (AI)
prostate cancer. A set of 81 genes was identified that were differentially expressed between ER-
and ER+ clinical breast tumors and breast cancer cell lines and that showed concordant expression
in AI versus AS (androgen sensitive) prostate cell lines. This common gene signature of hormone
independence was used to identify a subset of clinically localized primary prostate tumors that
shared extensive similarities in gene transcription with both ER- breast and AI prostate cell lines
and that tended to show concurrent deactivation of the androgen signaling pathway. Both ER-
breast and AI prostate cell lines were significantly enriched for transcriptional targets of signaling
via epidermal growth factor receptor (EGFR).
Conclusion: This study indicates that the growth- and survival-promoting functions of hormone
receptors can be bypassed in a subset of both breast and prostate cancers by the same growth
factor signaling pathways, which holds implications for the use of targeted therapy regimens.
Background
In 2006, on the order of 234,000 men and 213,000
women were diagnosed with prostate cancer and breast
cancer, respectively, and about 27,000 men and 41,000
women died (American Cancer Society statistics). Steroid
hormone receptor signaling has been linked to all stages
of prostate and breast carcinogenesis [1,2]. Initial treat-
ment of clinically localized prostate cancer (PCA) and
invasive breast cancer (IBC) usually involves surgical
removal of the cancerous tissue or radiation therapy. The
clinical use of adjuvant anti-androgen therapy in PCA and
of anti-estrogen therapy in IBC has aided greatly in pro-
longing or preventing disease recurrence, as the majority
of these cancers, at least initially, depend upon their asso-
ciated hormones for growth. However, significant frac-
tions of PCA and IBC either initially present as hormone
independent or develop hormone independence over the
course of anti-hormone therapy [3,4]. In the case of IBC,
hormone independence correlates closely with expression
of the estrogen receptor alpha (ER), with 30–35% of IBC
being ER-negative (ER-) and exhibiting no requirement of
estrogen for growth [3,5]. Except for the fraction of ER-
IBC that express HER2/neu, no targeted therapy is cur-
rently in widespread use for ER- IBC. In the case of
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advanced PCA, androgen ablation therapy effectively
results in tumor regression over the short-term; in most
cases, however, the recurrence of highly aggressive and
metastatic prostate cancer that is resistant to hormone
therapy occurs as a result [1,4].
Breast and prostate cancers share much in common with
each other, in that they both manifest as either hormone
dependent or independent. The hypothesis explored in
this present study is that the molecular mechanisms of
acquirement of hormone independence are similar
between IBC and PCA [4]. Global gene expression profil-
ing studies, carried out in breast and prostate cancers sep-
arately, indicate that on the order of hundreds or even
thousands of genes might be involved in hormone inde-
pendence in each disease [6-8]. If a select set of genes com-
mon to hormone independent breast and prostate cancers
could be identified, it might be indicative of a core tran-
scriptional program on which attention could be focused.
The main strategy of this study was to look for patterns of
enrichment, i.e. to look for a non-random amount of
shared overlap between distinct sets of genes associated
separately with either breast or prostate cancers. Such a
pattern of enrichment may involve only a fraction of the
genes from each cancer type and yet may hold biological
and clinical significance.
Results
A gene expression signature of ER-, hormone-independent 
clinical breast tumors that is partially manifested in ER- 
breast cancer cell lines
The basic approach of this study was to first derive sepa-
rate gene expression signature patterns of hormone inde-
pendence from breast and prostate cancers and then to
determine whether the two signatures shared significant
similarity with each other. A gene transcription signature
of ER- (hormone-independent) versus ER+ (hormone-
dependent) invasive breast cancer (IBC) was defined by
selecting genes showing differential expression (p<0.01)
in each of two independent mRNA profile datasets of 295
clinical IBC (the dataset from van de Vijver et al., ref [9],
with 69 profiles from ER- tumors) and 286 tumors (the
dataset from Wang et al., ref [10], with 77 ER- profiles). Of
the 2486 uniquely identified genes in this ER-status signa-
ture, 1332 were higher in the ER- tumors.
The expression patterns of the ER-status gene signature as
derived from clinical IBC were further examined in an
additional dataset of breast cancer cell lines from Bild et
al. [11], which consisted of 28 mRNA profiles represent-
ing 18 different cell lines (ten of them ER-). As expected, a
significant portion of the clinical ER-status signature
showed the corresponding expression patterns in cell
lines. Out of the 1332 genes found to be higher in ER-
clinical tumors, 223 were higher in ER- cell lines (p<0.01),
while 848 showed no such trend (p>0.1). The intersection
of the clinical and cell line breast cancer signatures was
termed the "core breast ER-status signature" and consisted
of 223 ER- genes (Venn diagram represented in Figure 1)
and 194 ER+ genes (p<0.01 in each of Bild, van de Vijver,
and Wang datasets). This core signature pattern was con-
sidered to be independent of the tissue or environmental
context. The suggestion that a set of genes associated with
hormone independence in breast cancer were regulated in
vivo but not in vitro seemed intriguing but was not further
explored in this study.
The expression patterns of the clinical breast ER-status sig-
nature were visualized as heat maps in both the clinical
and cell culture profile datasets (Figure 2). From the heat
map representation, it was apparent that a small fraction
of the breast tumors in the Wang profile dataset that were
classified as ER+ by immunohistochemistry showed gene
expression patterns more characteristic of ER- tumors, as
Genes associated with hormone independence in breast can- cer share significant overlap with genes associated with hor- mone independence in prostate cancer Figure 1
Genes associated with hormone independence in breast can-
cer share significant overlap with genes associated with hor-
mone independence in prostate cancer. Venn diagram 
showing the overlap between the following sets of genes: (1) 
genes more highly expressed in clinical ER- over ER+ breast 
tumors (p<0.01 in each of the RNA profile datasets from van 
de Vijver et al. and Wang et al.), (2) genes more highly 
expressed in ER- over ER+ cell lines (p<0.01 in the profile 
dataset from Bild et al.), and (3) genes more highly expressed 
in androgen independent (AI) over androgen sensitive (AS) 
prostate cell lines (p<0.05 in the dataset from Zhao et al.). 
Core breast ER-status signature, genes shared between the clin-
ical breast tumor and breast cancer cell line sets. Common sig-
nature of hormone independence, genes shared between all 
three sets.BMC Genomics 2007, 8:199 http://www.biomedcentral.com/1471-2164/8/199
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well as low ER mRNA. Similarly, one particular breast can-
cer cell line, HCC1428, was designated as ER+ [12] but
from its profile appeared more similar to ER- cell lines. In
the heat map representation (Figure 2), the ER- tumor and
cell line profiles were ordered by increasing similarity to
the overall ER- expression pattern. The small fraction of
ER- tumors which did not fit the pattern tended to have
high RNA expression of the HER2 oncogene. In addition,
the ER-, HER2+ SKBR3 cell line did not fit the pattern of
the other ER- cell lines. All of this indicated that the core
breast ER-status signature (Figure 2) was a pattern of ER-,
HER2- breast cancer, with the ER-, HER2+ breast cancers
having a different pattern, as has been indicated in previ-
ous expression profiling studies [6,7,12].
A gene expression signature common to ER- breast cancer 
and AI, hormone-independent prostate cancer cell lines
Unlike breast cancer, there are currently no well-defined
molecular markers of hormone-independent prostate
cancer. For example, expression of the androgen receptor
(AR) does not appear to correlate with response to hor-
mone therapy in prostate cancer, and AR protein is
expressed fairly homogeneously in primary tumors, recur-
rent local tumors, and metastases [1]. It was therefore dif-
ficult to define a signature of hormone-independence
from profiles of clinical prostate tumors alone. However,
a number of prostate cancer cell lines have been estab-
lished that are classified as either androgen sensitive (AS),
which respond to androgen stimulation, and androgen
insensitive (AI), which do not respond. As discussed
below (see Discussion and [4]), there are several known
mechanisms by which prostate cancers may develop
resistance to hormone therapy. While the cell lines con-
sidered here were entirely androgen pathway independ-
ent, other prostate cancers develop hypersensitivity to
androgen receptor pathway signaling; this latter type of
hormone therapy resistant cancer was not considered in
this study.
Gene expression patterns of ER- clinical breast cancer are observed in both breast and prostate cancer cell lines Figure 2
Gene expression patterns of ER- clinical breast cancer are observed in both breast and prostate cancer cell lines. Heat map 
representation for 2486 unique named genes differentially expressed between ER+ and ER- breast tumors (p<0.01 in both van 
de Vijver and Wang RNA profile datasets, 1332 higher in ER-). Expression patterns are represented as a color map. Each row 
represents a gene; each column represents a sample. The level of expression of each gene in each sample is represented using 
a yellow-blue color scale (yellow: high expression). Patterns corresponding to the 2486 genes are shown in both the Bild pro-
file dataset of 18 breast cancer cell lines (ten ER-) and the Zhao dataset of eight prostate cell lines (AS, androgen sensitive; AI, 
androgen independent; gray denotes missing values or unrepresented genes). The order of the genes is the same for each of 
the datasets. Corresponding expression patterns for genes ER, PR, HER2, and EGFR are also shown. The order of the breast 
and prostate cell lines profiles is the same as that for Figure 4 (where they are labeled by name). Genes and associated expres-
sion values are available in Additional File 1.BMC Genomics 2007, 8:199 http://www.biomedcentral.com/1471-2164/8/199
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Table 1: Genes with elevated mRNA levels in common signature of hormone independence (Figure 1)
Entrez Name Title Entrez Name Title
87 ACTN1 actinin, alpha 1 5329 PLAUR plasminogen activator, urokinase receptor
136 ADORA2B adenosine A2b receptor 5359 PLSCR1 phospholipid scramblase 1
390 ARHE Rho family GTPase 3 5621 PRNP Prion protein (p27–30)
824 CAPN2 calpain 2, (m/II) large subunit 6732 SRPK1 SFRS protein kinase 1
858 CAV2 caveolin 2 7272 TTK TTK protein kinase
994 CDC25B cell division cycle 25B 7296 TXNRD1 thioredoxin reductase 1
1075 CTSC cathepsin C 7378 UP uridine phosphorylase 1
1284 COL4A2 collagen, type IV, alpha 2 7398 USP1 ubiquitin specific peptidase 1
1786 DNMT1 DNA (cytosine-5-)-methyltransferase 1 8882 ZNF259 zinc finger protein 259
1969 EPHA2 EPH receptor A2 8898 MTMR2 myotubularin related protein 2
2000 ELF4 E74-like factor 4 (ets domain) 9056 SLC7A7 solute carrier family 7, member 7
2023 ENO1 enolase 1, (alpha) 9322 TRIP10 thyroid hormone receptor interactor 10
2037 EPB41L2 erythrocyte membrane protein band 4.1-like 2 10403 KNTC2 kinetochore associated 2
2131 EXT1 exostoses (multiple) 1 10479 SLC9A6 solute carrier family 9, member 6
2182 ACSL4 acyl-CoA synthetase long-chain member 4 10644 IMP-2 IGF-II mRNA-binding protein 2
2633 GBP1 guanylate binding protein 1, interferon-inducible 10946 SF3A3 splicing factor 3a, subunit 3, 60 kDa
2920 CXCL1 chemokine (C-X-C motif) ligand 2 25937 DKFZP586I1419 WW domain containing transcription regulator 1
3383 ICAM1 intercellular adhesion molecule 1 (CD54), human 
rhinovirus receptor
26031 OSBPL3 oxysterol binding protein-like 3
3569 IL6 interleukin 6 (interferon, beta 2) 26064 RAI14 retinoic acid induced 14
3575 IL7R interleukin 7 receptor 29083 HSPC135 HSPC135 protein
3600 IL15 interleukin 15 29970 SCHIP1 schwannomin interacting protein 1
3801 KIFC3 kinesin family member C3 29980 DONSON downstream neighbor of SON
3934 LCN2 lipocalin 2 (oncogene 24p3) 55003 PAK1IP1 PAK1 interacting protein 1
4478 MSN moesin 56913 C1GALT1 glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase
4907 NT5E 5'-nucleotidase, ecto (CD73) 140885 PTPNS1 protein tyrosine phosphatase, non-receptor type substrate 1
5271 SERPINB8 serpin peptidase inhibitor, clade B
From an mRNA profile data of eight different prostate cell
lines, three of them AI, a set of 1793 genes that showed
differential expression (p<0.05) between AS and AI was
obtained, 952 of these genes being higher in AI. The over-
lap of these 952 AI genes with the 223 core breast ER- sig-
nature (Figure 1) was 51; by chance, around 19 genes
would have been expected to overlap, which makes the
observed overlap of 51 highly significant (p = 1E-11, one-
sided Fisher's exact). A list of the 51 common prostate AI/
breast ER- genes is provided in Table 1 (heat map repre-
sentation in Figure 2, associated gene expression values
provided in Additional File 1). Only three genes in the list
(KNTC2, EXT1, and CDC25B) were annotated by Gene
Ontology as having roles in the cell cycle or cell division,
and so the 51 genes as a group do not appear to represent
a program of general cellular proliferation.
The 952 prostate AI genes also shared highly significant
overlap with the breast ER- clinical and breast ER- cell line
gene sets individually (189 genes, Fisher's exact p = 1E-16;
and 194 genes, p = 1E-39, respectively, see Figure 1). Sim-
ilarly, the 841 genes higher in AS over AI prostate cell lines
shared a highly significant overlap of 30 with the set of
194 in the core breast ER+ signature (expected 11, Fisher's
Table 2: Genes with diminished mRNA levels in common signature of hormone independence (Figure 2)
Entrez Name Title Entrez Name Title
367 AR androgen receptor 7494 XBP1 X-box binding protein 1
388 RHOB ras homolog gene family, member B 7644 ZNF91 zinc finger protein 91
414 ARSD arylsulfatase D 8349 HIST2H2BE Histone 2, H2be
780 DDR1 discoidin domain receptor family, member 1 10140 TOB1 transducer of ERBB2, 1
1153 CIRBP cold inducible RNA binding protein 10229 COQ7 coenzyme Q7 homolog, ubiquinone
1154 CISH cytokine inducible SH2-containing protein 11201 POLI polymerase (DNA directed) iota
1363 CPE carboxypeptidase E 23199 KIAA0182 KIAA0182 protein
2065 ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 23247 KIAA0556 KIAA0556 protein
2746 GLUD1 glutamate dehydrogenase 1 25800 SLC39A6 solute carrier family 39, member 6
2804 GOLGB1 golgi autoantigen, golgin subfamily b, 1 27075 TM4SF13 tetraspanin 13
3169 FOXA1 forkhead box A1 27134 TJP3 tight junction protein 3
3382 ICA1 islet cell autoantigen 1, 69 kDa 51361 HOOK1 hook homolog 1 (Drosophila)
5241 PGR progesterone receptor 51478 HSD17B7 hydroxysteroid (17-beta) dehydrogenase 7
5349 FXYD3 FXYD domain containing ion transport regulator 3 55930 MYO5C Myosin VC
6509 SLC1A4 solute carrier family 1 (glutamate/neutral amino acid transporter), member 
4
56654 NPDC1 neural proliferation, differentiation and control, 1BMC Genomics 2007, 8:199 http://www.biomedcentral.com/1471-2164/8/199
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exact p = 1E-07). A list of these 30 common prostate AS/
breast ER+ genes is provided in Table 2. Of the 30 genes,
six (CISH, KIAA0182, ICA1, PGR, SLC1A4, XBP1) were up-
regulated by estrogen signaling (in cluster "B" from ref 13)
and six (KIAA0182,  GLUD1,  FOXA1,  FXYD3,  NPDC1,
HIST2H2BE) were up-regulated (p<0.001) by androgen
signaling, based on analysis of data from published RNA
profiling studies of breast cancer [13] and prostate cancer
[14] cell cultures, respectively.
Enrichment of the prostate AI/AS gene signature within
the breast cell line ER-/ER+ signature was also demon-
strated using an alternative analytical technique (known
as "Q1–Q2" in Tian et al., ref 15), in which all the genes
represented in the Bild breast cell line dataset were ranked
by over-expression in ER- over ER+ cell lines, and the rel-
ative positions of the prostate AI and AS gene sets were
each evaluated within the ranked list from the breast data-
set. Over any randomly selected set of genes from the
prostate dataset, and over any random assignment of the
profile labels in the breast dataset, the AI genes were
enriched within the ER- genes and the AS genes, within
the ER+ genes (p = 0.0001 and p = 0.01, respectively). The
81 genes concurrent between AI/AS prostate cancer and
the ER-/ER+ prostate signatures was termed a common
signature of hormone independence. While these 81
genes represented significant similarities between hor-
mone independent breast and prostate cancers, there were
many more genes not shared between the two (Figures 1
and 2), as would expected when comparing these two
rather different systems.
Identification of a subset of clinically localized prostate 
tumors having the gene signature of hormone 
independence and showing repression of androgen 
signaling
Primary IBC presents as either hormone dependent (ER+)
or independent (ER-). Based on the observed overlap
between an in vitro gene signature of androgen independ-
ence in prostate cancer and the signature of estrogen inde-
pendence in clinical breast tumors (Figures 1 and 2), it
seemed plausible that a subset of androgen independent
primary prostate tumors could be defined using the breast
tumor expression profile data. Three independent mRNA
profile datasets of clinically localized prostate cancer
(PCA) were considered: from Glinsky et al. [16] of 79
tumors, from Yu et al. [17] of 60 tumors, and from
Lapointe et al. [18] of 62 tumors. The PCA profiles in each
Gene expression patterns of ER- breast cancer are observed in a subset of clinically localized prostate cancer (PCA) Figure 3
Gene expression patterns of ER- breast cancer are observed in a subset of clinically localized prostate cancer (PCA). Heat map 
representation for 417 unique genes differentially expressed between ER+ and ER- clinical breast tumors and cell lines (from 
Figure 2). The patterns corresponding to these genes are shown in three independent RNA profile datasets of PCA from Glin-
sky et al. [14], Yu et al. [15], and Lapointe et al. [16]. The PCA profiles are ordered from those that share more similarity with 
the ER+ breast cancer pattern to those that share more similarity with the ER- breast cancer pattern. The order of the genes 
is the same for each dataset represented. For each dataset, the average expression of a set of 559 genes induced by synthetic 
androgen R1881 in vitro in a dataset from Chen et al. [18] is also represented. The order of the breast and prostate cell lines 
profiles is the same as that for Figure 4. Genes and associated expression values are available in Additional File 2.BMC Genomics 2007, 8:199 http://www.biomedcentral.com/1471-2164/8/199
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of the three datasets were ordered based on the extent of
similarity in expression patterns (by Pearson's correlation
coefficient) with that of the 417 genes in the core breast
ER-status signature (Figure 2).
For each PCA profile dataset, a sizable fraction of the
tumors were significantly correlated (p<0.01) with the ER-
status signature (Glinsky: 52%, Yu: 52%, Lapointe: 32%),
some of the PCA having patterns similar to ER- IBC, others
to ER+ IBC. When selecting a random set of 417 genes
from the Glinsky dataset to represent the ER-status signa-
ture, none of Glinsky tumors shared significant similari-
ties to the random pattern as expected. These observations
indicated that the set of genes associated with hormone
independence in breast tumors are coordinately expressed
in PCA, which was further evident when viewing the asso-
ciated expression patterns as heat maps (Figure 3, associ-
ated gene expression values provided in Additional File
2). For the genes high in ER- IBC, a sizable fraction were
also high in a subset of the PCA tumors; in these same
tumors, a sizable fraction of the ER+ genes were down.
Where the breast cancer cell lines and the PCA shared
common expression patterns, the associated genes also
showed concordant expression in the prostate cell line
data. When comparing the subset of clinical PCA having
significant similarities (p<0.01) to ER- breast tumors and
cell lines with the subset of PCA similar to ER+ breast, the
androgen receptor (AR) was significantly decreased
Genes associated with hormone independence in both breast and prostate cancer are enriched for transcriptional targets of  the EGFR signaling pathway Figure 4
Genes associated with hormone independence in both breast and prostate cancer are enriched for transcriptional targets of 
the EGFR signaling pathway. (A) Heat map representation for 81 unique genes in the common signature of hormone independ-
ence (from Figures 1 and 2). The patterns corresponding to these genes are shown in the breast and prostate cell line profile 
datasets and in a dataset from Creighton et al. [21] of MCF-7 cell lines with activated oncogenes HER2, MEK, Raf, or EGFR. The 
order of the genes is the same for the datasets. The set of genes both associated with ER- and AS cell lines and activated by 
EGFR (p<0.01) are highlighted. (B) Classification of the breast and prostate cell lines as "EGFR-like" or "ERBB2-like," using the 
entire sets of genes from the Creighton dataset that were differentially expressed (p<0.01, irrespective of the Bild and Zhao 
datasets) in the EGFR or HER2 MCF-7 cell lines, respectively, as compared to controls. Genes and associated expression values 
are available in Additional File 3.BMC Genomics 2007, 8:199 http://www.biomedcentral.com/1471-2164/8/199
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(p<0.01) in PCA similar to ER- breast for the Glinsky and
Lapointe datasets but not the Yu datasets. KLK3, which
encodes prostate-specific antigen (PSA), was decreased
(p<0.01) in PCA similar to ER- breast for the Yu and
Glinksy but not the Lapointe datasets.
Transcriptional targets of the androgen signaling pathway
have been defined previously using gene expression pro-
filing of cell cultures [14,19]. From the profile dataset
from Chen et al. [14], a set of 559 unique named genes
showing induction (p<0.001) by synthetic androgen
R1881 were obtained. Relatively few genes in the com-
mon signature of hormone independence (Figure 2) were
androgen-inducible, six of them in the set of 30 AS/ER+
genes and three in the set of 51 AI/ER- genes. Of the 223
ER- genes and 194 ER+ genes in the core ER-status signa-
ture, 22 and 13, respectively, were R1881-inducible.
When comparing the subset of clinical PCA having signif-
icant similarities (p<0.01) to ER- breast with the subset of
PCA similar to ER+ breast, the PCA similar to ER- showed
lower average expression of the R1881-inducible genes
(Glinsky p<0.0002, Yu p<0.0007, Lapointe p<0.09, t-test,
see also Figure 3). Across all of the PCA profiles, the t-sta-
tistic of the similarity with the ER- core signature pattern
was inversely correlated (p<0.05, Pearson's) with the aver-
age expression of R1881-inducible genes in each of the
three datasets. These patterns indicated that the androgen
signaling pathway tends to be deactivated or suppressed
in PCA exhibiting the gene signature of hormone inde-
pendence.
ER- breast and AI prostate cell lines are significantly 
enriched for transcriptional targets of the EGFR pathway
For clues as to what molecular pathways may be repre-
sented in the common gene signature of hormone inde-
pendence (Figure 2), transcriptional targets of various
pathways from public datasets were examined. Pathways
considered included: Myc, c-Src, beta-catenin, E2F3, and
H-Ras, from the expression profile dataset from Bild et al.
[11]; Akt, from the dataset by Majumder et al. [20]; cyclin
D1, from the dataset by Lamb et al. [21]; and Her2, EGFR,
MEK, and Raf, from the dataset by Creighton et al. [22]. In
the previous Creighton study, ER+ MCF-7 breast cancer
cells were made to stably over-express EGFR or constitu-
tively activate erbB-2, Raf, or MEK; which resulted in these
cells exhibiting estrogen-independent growth and the
down-regulation of ER expression. Of all the pathway
gene signatures considered in this present study, the
EGFR, MEK, and Raf signatures shared significant similar-
ities with the common hormone independence signature.
Of the 734 genes up-regulated (p<0.01) by EGFR, the
1238 genes up-regulated by MEK, and the 618 up-regu-
lated by Raf: 16, 15, and 12, respectively, were shared with
the 51 AI prostate/ER- breast genes of Table 1 (one-sided
Fisher's exact p<4E-09,  p<2E-05, and p<2E-06, respec-
tively). Conversely, of the 940 genes down-regulated by
EGFR, the 1182 genes down-regulated by MEK, and the
988 down-regulated by Raf: 11, 8, and 15, respectively,
were shared with the 30 AS prostate/ER+ breast genes of
Table 2 (Fisher's exact p<2E-06, p = 0.003, and p<3E-10,
respectively).
The expression patterns of the hormone independence
signature were viewed as a heat map in the context of the
patterns of the MCF7 cell lines with activated HER2, MEK,
Raf, or EGFR (Figure 4A, associated gene expression values
provided in Additional File 3). Most of the ER- breast
tumors and cell lines over-expressed EGFR mRNA, and
those that did not tended to over-expressed HER2 (Figure
2, Figure 4A). The AI prostate cell lines, however, did show
over-expression of HER2 at the mRNA level. In addition,
using the entire set of 1674 unique genes differentially
expressed in the MCF7-EGFR cell line relative to control
(p<0.01, 734 up-regulated), the Bild breast and Zhao
prostate cell lines were stratified based on similarity
(p<0.01, Pearson's correlation) to the EGFR gene signature
pattern (Figure 4B). Most all of the ER- breast cell lines
(with the exception of MDA-MD-453 and HER2+ SKBR3),
all of AI prostate cell lines, and none of the ER+ or AS cell
lines (with the exception of HCC1428) shared extensive
similarities with the EGFR transcriptional signature. A
similar analysis was carried out using the HER2 gene sig-
nature, but no stratification on the basis of hormone
insensitivity was observed. The hormone independence
signature showed no enrichment for HER2 transcriptional
targets (Figure 4A).
Discussion
One of the "holy grails" of both breast and prostate cancer
research is to determine how these cancers acquire hor-
mone independence and how best to treat them when
they do. A number of molecular mechanisms have been
postulated to explain resistance to hormone therapy in
prostate cancer. One class of resistant prostate tumors
continues to rely upon androgen receptor (AR) signaling
through a number of means, including: over-expression of
the AR gene, through DNA amplification or some other
mechanism [14,23]; "promiscuous" point mutation in
AR, allowing the receptor to be activated by steroids other
than androgen, including anti-androgens and estrogen
[24]; and ligand-independent activation of AR, mediated
by oncogenes such as ERBB2 or HRAS [25]. While tumors
that fall under the above may often be referred to as
"androgen independent" [4], for the purposes of this
present study we must draw a distinction between the
above class of hormone therapy resistant prostate cancer
and a second class, which bypasses AR function com-
pletely and does not rely upon androgens for growth. This
second class is what appears to be involved in the gene sig-
nature of hormone independence uncovered here asBMC Genomics 2007, 8:199 http://www.biomedcentral.com/1471-2164/8/199
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being common to both ER- breast cancer and prostate
cancer that is completely AI.
The specific alternative signaling pathways that allow
prostate tumors to bypass AR have been somewhat elu-
sive, one candidate pathway possibly involving BCL2 [4].
This present study has implicated EGFR signaling has
playing an important role in bypassing AR. While tran-
scriptional targets of EGFR were enriched in AI prostate
cancer (Figure 4), EGFR mRNA itself did not appear ele-
vated in AI cell lines. Neither was EGFR mRNA consist-
ently elevated in the clinical PCA samples that exhibited
an ER-/AI molecular phenotype (Figure 3). However,
EGFR protein itself is elevated in AI over AS cell lines [26].
Recent studies have found EGFR protein expression in
tumor tissues to be strongly associated with hormone
refractory status [27-29]. The EGFR tyrosine kinase inhib-
itor gefitinib causes cell cycle arrest and initiates apoptosis
in primary PCA cultures and in PCA cell lines, including
DU145 and PC3 as well as LNCaP [26]. In studies using
the AI cell line PC3, suppression of EGF-R signaling
reduced the incidence of prostate cancer metastasis in
nude mice [30].
This present study indicates that a subset of primary PCA
presents as hormone independent, prior to patient treat-
ment with adjuvant anti-androgen therapy (Figure 3). It
has been previously thought that a sub-population of
androgen-resistant cells might coexist with androgen-
dependent cells within the tumor, and that anti-androgen
therapy would therefore kill off the dependent cells and
leave the resistant cells to thrive [1]. This study lends sup-
port to an adjuvant therapy strategy of combining EGFR
inhibitors with anti-androgens. One question to consider
in designing clinical trials testing this treatment regimen is
whether PSA recurrence would be a suitable endpoint, as
AI prostate cancer may not express PSA (Figure 3). The
ability to identify a hormone independent subset of pri-
mary breast cancer using ER as a biomarker has implica-
tions for selecting the course of adjuvant treatment [3]. If
a subset of primary prostate tumors could be diagnosed in
the clinic as being hormone independent, it could warrant
more aggressive treatment with alternative therapies to
anti-androgens. Individual genes in the list of 81 in the
gene signature of hormone independence might be good
candidates for prognostic markers in PCA, or several genes
in the signature could perhaps be used together.
In other studies, gene expression profiling has been car-
ried out on hormone refractory metastases of prostate
cancer [31,32]. One issue with comparing results derived
from those datasets with this present study's gene signa-
ture of hormone independence is that, as discussed above,
these metastases likely represent several mechanisms of
hormone therapy resistance, not simply the use of EGFR-
mediated bypass of AR function, as appears to be mani-
fested in the AI prostate cell lines analyzed here. Genes
expressed in the EGFR-dependent AI subtype may not be
uniformly expressed in all varieties of hormone refractory
cancers. The dataset from ref [32] was analyzed here in the
context of the datasets used in this study; when consider-
ing the genes high in hormone-refractory prostate metas-
tases compared to PCA, no significant overlap of these
genes was observed with the genes high in the AI prostate
cell lines or the ER- breast tumors (results not shown). A
number of expression profiling studies using prostate
tumor xenografts acquiring resistance to hormone therapy
have been carried out [14,33-36]; many of these studies
appear to represent cancers that develop hypersensitivity
to androgen pathway activation, rather than androgen
pathway independence. The hormone independent gene
signature of this present study did not show coordinate
expression in a profile dataset from Chen et al. [14] of hor-
mone therapy-resistant prostate tumors xenografts
(results not shown); as these tumor xenografts uniformly
up-regulated AR, it could be presumed that these
xenografts represented a model of increased sensitivity to
androgen levels.
One limitation with this present study is the small
number of prostate cancer cell lines for which gene expres-
sion profile data was available (five AS and three AI). Pro-
filing studies in breast cancer indicate that there are at
least two subtypes of ER- IBC, a HER2+ subtype and a
"basal" subtype [6,7,12]. Interestingly, recent studies indi-
cate that a subset of ER- breast cancer may rely upon the
androgen pathway rather than the estrogen pathway
[37,38], though this does not appear to represent the sub-
set of ER- considered here, as androgen-regulated genes
were not enriched in the ER- gene signature of Figure 2
(results not shown). If more prostate cancer cell lines were
profiled, it might uncover additional subtypes of AI PCA
to the EGFR-dependent subtype uncovered here. The
basal subtype of ER- IBC also appears to rely upon EGFR
signaling (Figure 4). A number of clinical trials testing the
efficacy of EGFR tyrosine kinase inhibitors (TKIs) in breast
cancer treatment are underway. Initial phase II studies
have suggested that the EGFR TKIs do not have a high effi-
cacy in a heavily pre-treated population of patients with
metastatic breast cancer; however, in patients with hor-
mone therapy-resistant ER+ tumors, EGFR inhibition
does appear to have a significant therapeutic effect [39]. In
at least one small trial, there was evidence of only mini-
mal efficacy in advanced, metastatic ER- breast cancer
[39], though one could make the conjecture that anti-
EGFR therapy might be more effective in less advanced
cancers.
The 81 genes in the signature of hormone independence
common to prostate and breast is a much shorter set com-
pared to the hundreds of genes associated separately with
either prostate or breast (Figures 1 and 2). One mayBMC Genomics 2007, 8:199 http://www.biomedcentral.com/1471-2164/8/199
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expand the set of 81 somewhat by using slightly less strin-
gent statistical cutoffs. At the same time, the set of 81 may
provide a good starting point for further study. Interest-
ingly, a number of the 51 genes higher in AI prostate and
ER- breast were previously associated with the immune
response, including ELF4, GBP1, CXCL2, IL6, IL7R, and
IL15. IL6 (interleukin 6) in particular – indicated here to
be a transcriptional target of the EGFR pathway (Figure 4)
– has been shown to promote prostate tumor growth and
to play a role in the interaction between epithelial and
stromal cells in prostate cancer [40]. One next step in
studying these genes would likely be validation of their
expression patterns in breast and prostate tissues or cell
lines, using some alternative technique from microarrays,
such as westerns or quantitative RT-PCR; it is expected,
however, that most of the genes in the set of 81 would val-
idate, as their expression patterns were observed in multi-
ple profile datasets generated on different microarray
platforms, which in itself could be considered validation
[41].
Conclusion
In conclusion, the hope for this study is that it may aid in
the development of therapy regimens to target the subset
of breast and prostate cancers that up until the present
have been the most difficult to treat.
Methods
The gene expression profile datasets used in this study
were all publicly available. From the 66 PCA profiles
described in the study by Yu et al. [15], 60 were available
for this present study (collection for this dataset was facil-
itated by A.M. Chinnaiyan and the Oncomine team).
Recent evidence emerged that the MDA-MB-435 cell line
was not breast but melanoma [42] and so the MDA-MD-
435 profiles in the Bild dataset [11] were removed from
the analysis. Gene expression values in each dataset were
log-transformed. Gene expression values in the clinical
breast tumor and cell line profile datasets were centered
on the centroid mean of ER- and ER+. Values in the Zhao
prostate cell line profile dataset [8] were centered on the
centroid mean of AS and AI. Clinical prostate tumor data-
sets were transformed to standard deviations from the
median. For the androgen dataset from Chen et al. [14],
expression values within the AR+ group of samples were
transformed to standard deviations from the mean; values
within the vector group of samples were separately trans-
formed. Expression values in the Creighton MCF-7 dataset
[22] were centered on the mean of the MCF-7/lt-E2 con-
trol group.
As the expression profile datasets were generated on dif-
ferent platforms, and as many of the genes represented
were measured on multiple probes in any one dataset, a
method to select the optimal probe to represent each gene
in an unbiased fashion was used when joining multiple
datasets. For the Affymetrix array datasets, the probe with
the greatest variation across samples represented the gene.
For the cDNA microarray datasets (Zhao cell line and
Lapointe PCA), the probe with the most unflagged values
across samples, followed by the probe with the greatest
variation, represented the genes. The Entrez Gene identi-
fier was used in mapping genes across datasets. Two-sam-
ple  t-tests determined significant differences in gene
expression between groups of samples. For the Chen
androgen dataset, the Pearson's correlation between gene
expression and the log of the concentration of R1881
determined significance of R1881 induction. Expression
values were visualized as heat maps using the Cluster [43]
and Java TreeView software [44]. Prior to heat map gener-
ation, genes were manually sorted using Microsoft Excel
in order to highlight gene groups of interest.
The one-sided Fisher's exact test determined significance
of overlap between any two distinct sets of genes. Q1–Q2
enrichment analysis [15] was carried out essentially as
described in ref [45]. For "stratifying" a set of profiles in a
given dataset on the basis of a pre-defined expression pat-
tern (e.g. stratifying the clinical PCA profiles using the ER-
status gene signature in Figure 3), each gene involved in
the pattern was represented as "1" or "-1" (for up or down,
respectively), and the Pearson's correlation coefficient was
computed between the pattern and each individual pro-
file (with significance by two-sided t-test).
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